ISRCTN16417487Active, not recruitingUnknown
3TR-ABC multiomics in asthma and healthy controls
niversity of Leicester0 sites100 target enrollmentStarted: February 6, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Mild/moderate asthma controls
- •1. Adult (=18 years old)
- •2. Diagnosed with mild/moderate controlled asthma:
- •2.1 Low/medium dose of ICS/LABA +/- LTRA
- •2.2 ACQ < 1.5
- •2.3 Markers of T2 inflammation (B-eos = 0.15 actual or = 0.30 the last year or Sputum eos = 3%, FeNO = 25, allergens positivity)
- •2.4 Markers of T2 low inflammation (B-eos < 0.15 actual or < 0.30 the last year of sputum eos < 3%, FeNO < 25, allergens negativity)
- •2.5 No exacerbations in the past 12 months
- •2.6 No need for prednisolone treatment
- •2.7 Not a direct candidate for biologic therapy
- •3. Be able to give valid written consent, and compliant with study procedures and study visits.
- •Healthy controls
- •1. Adult (=18 years old)
- •2. Healthy:
- •2.1 No current medication/therapy for autoimmune, inflammatory, or allergic diseases
- •2.2 No history of asthma or respiratory symptoms
- •2.3 No history of allergies
- •2.4 No upper or lower respiratory infections in the past 4 weeks
- •3. Be able to give valid written consent, compliant with study procedures and study visits
Exclusion Criteria
- •Mild/moderate asthma controls
- •1. Unable to understand written information due to language barriers.
- •2. Unable to give informed consent, i.e., patients who are incapable.
- •3. Unable to complete study visits.
- •Healthy controls
- •1. Unable to understand written information due to language barriers.
- •2. Unable to give informed consent, i.e., patients who are incapable.
- •3. Unable to complete study visits.
Investigators
Similar Trials
Recruiting
Not Applicable
3TR - ABC (Asthma Biologics Cohort) study and AIR-Bio-OCT study A part of the 3TR (Taxonomy, Treatment, Targets and Remission) Consortium for the identification of the molecular mechanisms of non-response to treatment, relapses, and remission in autoimmune, inflammatory, and allergic conditionsNL-OMON52133Amsterdam UMC75
Recruiting
Not Applicable
3TR Asthma Biologics Cohort (ABC) StudySevere AsthmaNCT06126692Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)600
Completed
Not Applicable
Prospective evAluatIon foR Inhalation Devices StudyCOPDAsthmaNCT01800994Elpen Pharmaceutical Co. Inc.750
Terminated
Phase 4
Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICSAsthmaNCT00486343Critical Therapeutics400
Completed
Phase 3
Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)AsthmaNCT00318708Milton S. Hershey Medical Center92